Immunoglobulin heavy diversity 3-9 (IGHD3-9)

Immunoglobulin heavy diversity 3-9 (IGHD3-9) is a gene segment in the immunoglobulin heavy chain locus on chromosome 14q32 that supplies diversity for the third complementarity-determining region (CDR3) of antibodies during V(D)J recombination in developing B cells. It is not a protein or receptor, but rather a short germline DNA segment rearranged with variable (IGHV) and joining (IGHJ) gene segments to generate the immense variety of antibody specificities in the adaptive immune system. IGHD gene segments do not encode whole proteins nor serve as therapeutic drug targets, but are key contributors to antigen recognition via their presence in mature immunoglobulin molecules. The diversity and biased usage of IGHD segments influence immune repertoire variability across individuals. As a genomic segment, IGHD3-9 does not have roles as a receptor, enzyme, transporter, or therapeutic target and therefore does not interact directly with drugs nor serve as a biomarker or source of safety concerns. There is a likely error or confusion in considering "IGHD3-9" as a drug target/receptor; it is a DNA segment rather than a protein, receptor, or enzyme. There are no drugs that directly target IGHD gene segments, nor known clinical biomarkers or safety issues associated specifically with IGHD3-9. The canonical name and abbreviation above are correct for genomic context, not for therapeutic targeting. Aliases (IGHD39, DXP1) refer to alternative databases or historic nomenclature, but do not change its function or classification. Molecular classification should only state “immunoglobulin diversity gene segment,” which is not a therapeutic class. IGHD3-9 is not a therapeutic target, receptor, or enzyme. It is a short genomic segment involved in generating diversity of antibody genes. Any classification as a target or listing drug interactions, mechanisms of action, biomarkers, or safety concerns is incorrect for this entity.

Other names

IGHD39DXP1IGHD3-9